J Ethnopharmacol:麦门冬汤通过PI3K/Akt/FOXO3a信号通路介导成纤维细胞活化调控M2巨噬细胞极化抑制肺纤维化

2023-10-23 紫菀款冬 MedSci原创 发表于上海

通过靶向巨噬细胞和PI3K/Akt/FOXO3a信号通路,评估麦门冬汤(MMDD)治疗肺纤维化(PF)的潜力。

背景肺纤维化(PF)是一种无法治愈、进行性和不可逆的肺部疾病,严重威胁着公众健康。尽管近几十年来取得了重大进展,但仍不清楚PF的机制,使得其治疗难度较大。在中国古代医学文献中,PF没有具体的疾病名称,根据其临床表现,PF在中医上常被归为“肺痿”或“肺痹”范畴。治疗虚热肺萎缩的经典方剂是麦门冬汤(MMDD)

MMDD由麦门冬、半夏、人参、甘草、粳米、大枣组成,具有清养肺胃,降逆下气等功效。大量的基础科学和临床研究表明,MMDD的原方或其加减方均可以减缓PF的进展。关于MMDD改善PF机制的研究主要集中在减轻炎症、抑制氧化损伤、抑制促纤维化因子表达、改善肺顺应性、抑制骨髓间充质干细胞向肺泡上皮细胞分化、增强肺细胞自噬活性等方面

研究目的:通过靶向巨噬细胞PI3K/Akt/FOXO3a信号通路,评估MMDD治疗PF的潜力。

方法:将60只小鼠随机分为5组(N = 12):对照组、BLM、BLM + MMDD(4、8、16 g/kg MMDD)组。BLM组和BLM + MMDD组经气管注射2 mg/kg BLM诱导PF,对照组经气管注射生理盐水诱导PF。11 d后,每个BLM + MMDD组每天口服指定剂量的MMDD(4、8或16 g/kg),第28天处死小鼠。

研究了MMDD对肺组织炎症、纤维化和M2巨噬细胞浸润的影响。此外,还检测了PI3K/Akt/FOXO3a通路中促纤维化因子和关键蛋白的调节。体外实验包括诱导M2型巨噬细胞,评估MMDD对成纤维细胞活化和PI3K/Akt/FOXO3a通路的影响。

结果:MMDD改善小鼠体重,减轻炎症,抑制M2巨噬细胞在小鼠肺组织中的浸润。下调促纤维化因子,如TGF-β1和PDGF-RB,以及成纤维细胞活化标志物。MMDD还对PI3K/Akt/FOXO3a信号通路中的关键蛋白具有调节作用。

结论:MMDD的抗PF作用可能是由于抑制M2巨噬细胞分泌促纤维化因子,从而抑制肺成纤维细胞中PI3K/Akt/FOXO3a信号的激活。MMDD已被证明是治疗PF的一种成功方法,但尚需进一步的研究来验证其在临床实践中的有效性。

 

原始出处:

Shuangshuang HE, Mengmeng SHEN, Lan ZHANG, Fang ZHANG, Yu LI. Maimendong decoction regulates M2 macrophage polarization to suppress pulmonary fibrosis via PI3K/Akt/FOXO3a signalling pathway-mediated fibroblast activation [published online ahead of print, 2023 Oct 19]. J Ethnopharmacol. 2023;117308. doi:10.1016/j.jep.2023.117308.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2164507, encodeId=27bd216450e89, content=肺虚热,有阴阳之分吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:40:02 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164511, encodeId=cfcf216451108, content=肺的纤维化的机理可能在大肠, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:49:07 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164524, encodeId=475921645242f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Tue Oct 24 06:44:07 CST 2023, time=2023-10-24, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2164514, encodeId=ce3c21645143b, content=有没有疏通胆汁的药物,看看有疗效吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:52:08 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164513, encodeId=12e62164513b8, content=肝脏的纤维化可能在胆囊, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:51:25 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省)]
    2023-10-24 ms8000001184766686 来自河北省

    肺虚热,有阴阳之分吗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2164507, encodeId=27bd216450e89, content=肺虚热,有阴阳之分吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:40:02 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164511, encodeId=cfcf216451108, content=肺的纤维化的机理可能在大肠, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:49:07 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164524, encodeId=475921645242f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Tue Oct 24 06:44:07 CST 2023, time=2023-10-24, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2164514, encodeId=ce3c21645143b, content=有没有疏通胆汁的药物,看看有疗效吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:52:08 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164513, encodeId=12e62164513b8, content=肝脏的纤维化可能在胆囊, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:51:25 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省)]
    2023-10-24 ms8000001184766686 来自河北省

    肺的纤维化的机理可能在大肠

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2164507, encodeId=27bd216450e89, content=肺虚热,有阴阳之分吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:40:02 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164511, encodeId=cfcf216451108, content=肺的纤维化的机理可能在大肠, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:49:07 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164524, encodeId=475921645242f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Tue Oct 24 06:44:07 CST 2023, time=2023-10-24, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2164514, encodeId=ce3c21645143b, content=有没有疏通胆汁的药物,看看有疗效吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:52:08 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164513, encodeId=12e62164513b8, content=肝脏的纤维化可能在胆囊, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:51:25 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省)]
    2023-10-24 ms2000000702445417 来自湖南省

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2164507, encodeId=27bd216450e89, content=肺虚热,有阴阳之分吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:40:02 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164511, encodeId=cfcf216451108, content=肺的纤维化的机理可能在大肠, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:49:07 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164524, encodeId=475921645242f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Tue Oct 24 06:44:07 CST 2023, time=2023-10-24, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2164514, encodeId=ce3c21645143b, content=有没有疏通胆汁的药物,看看有疗效吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:52:08 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164513, encodeId=12e62164513b8, content=肝脏的纤维化可能在胆囊, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:51:25 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省)]
    2023-10-24 ms8000001184766686 来自河北省

    有没有疏通胆汁的药物,看看有疗效吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2164507, encodeId=27bd216450e89, content=肺虚热,有阴阳之分吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:40:02 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164511, encodeId=cfcf216451108, content=肺的纤维化的机理可能在大肠, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:49:07 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164524, encodeId=475921645242f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Tue Oct 24 06:44:07 CST 2023, time=2023-10-24, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2164514, encodeId=ce3c21645143b, content=有没有疏通胆汁的药物,看看有疗效吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:52:08 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2164513, encodeId=12e62164513b8, content=肝脏的纤维化可能在胆囊, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5018583938, createdName=ms8000001184766686, createdTime=Tue Oct 24 02:51:25 CST 2023, time=2023-10-24, status=1, ipAttribution=河北省)]
    2023-10-24 ms8000001184766686 来自河北省

    肝脏的纤维化可能在胆囊

    0

相关资讯

European Radiology:弹性配准技术在特发性肺纤维化HRCT肺收缩评估中的应用!

近年来,肺血管重塑在间质性肺病(ILD)的发展和预后中的作用受到越来越多的关注,肺血管重塑可能是除肺纤维化之外评估IPF患者疾病严重程度的新型影像生物标志物。

STTT:秦燕团队揭示肺纤维化的血液检测和治疗方法

翻译调控是最佳调控途径,细胞质和线粒体翻译之间存在失衡。信号PI3K-mTOR的增加促进了细胞翻译,增加了多核糖体比例,但由于ROS不耐受,细胞核糖体总数减少;但线粒体核糖体保持稳定和耐受。

第八届全国间质性肺疾病学术会:肺纤维化的影像特征及诊断

11月26日来自北京医院的陈启航教授以《肺纤维化的影像特征及诊断》为题,为大家做精彩讲述。梅斯医学将重点加以整理,分享给各位同道。

Nature Communications:白细胞端粒长度是预测肺纤维化患者死亡率的重要生物标志物!

PF 患者的端粒长度是一种异质但具有预测性的生物标志物,与实足年龄相关。更短的 LTL可准确识别死亡风险最高的患者,从而可以更早、更精确地进行干预。

清华长庚呼吸科:新冠病毒肺炎后肺纤维化简明诊治建议(第一版)

重症新冠病毒性肺炎一般会经历病毒复制期、肺部炎症期、肺纤维化期等3个阶段。针对这3个阶段,分别要进行抗病毒、抗炎和抗纤维化治疗。

Front Immunol:使用生物信息学分析鉴定肺纤维化和肺动脉高压之间的共享基因特征

该研究提出淋巴细胞激活可能是影响PF和PH病因的关键途径,并确定了IGF1作为重要的与免疫相关的共同基因。这些数据发现为未来的研究和治疗PF和PH的新潜在治疗靶点提供了基础。